S241656 + FOLFOX6 + FOLFOX7

S241656 + FOLFOX6 + FOLFOX7 is a combination therapy consisting of the investigational small molecule inhibitor S241656 (formerly BDTX-4933) and the chemotherapy regimens FOLFOX6 or FOLFOX7. S241656, developed by Institut de Recherches Internationales Servier under a global licensing agreement with Black Diamond Therapeutics, is an oral, CNS-penetrant inhibitor designed to suppress oncogenic signaling from KRAS, HRAS, NRAS, and BRAF (Classes I, II, and III) while avoiding paradoxical MAPK activation. FOLFOX6 and FOLFOX7 are variants of the FOLFOX regimen, which includes oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU). This combination is being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors harboring RAS/MAPK pathway mutations, including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and biliary tract cancer (BTC).

Other names

BDTX-4933 + FOLFOX6 + FOLFOX7S241656 + FOLFOX